安洛丁尼布作为重复高度质瘤的单疗法或组合疗法:一项回顾性研究
Jun Yin1, Wenya Yin1,2, Linlin Zheng1
1Department of Radiation Oncology, Radiation Oncology Key Laboratory Of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Clinical Medicine Insights. Oncology
|July 12, 2023
概括
安洛丁尼布在复发性高度质瘤方面表现出良好的安全性和有效性,显著延长了无进展生存期 (PFS). 这种多位抗血管原剂显示为治疗这些具有挑战性的脑瘤的治疗选择.
科学领域:
- 神经瘤学神经瘤学
- 医学瘤学 医学瘤学
- 药理学 药理学是指药理学的学科.
背景情况:
- 复发的高度质瘤 (世卫组织分类级别III-IV) 构成了重大治疗挑战.
- 安洛丁尼布是一种多位抗血管原剂,其治疗潜力受到研究.
- 评估anlotinib在单一治疗或组合治疗中的疗效和安全性至关重要.
研究的目的:
- 评估anlotinib在治疗复发性高度质瘤中的安全性和有效性.
- 为了比较anlotinib单一治疗与组合治疗的结果.
- 建立anlotinib作为复发性质瘤的潜在治疗选择.
主要方法:
- 追溯性研究包括29名患有复发性高度质瘤的患者 (2019年6月至2022年6月).
- 患者接受口服安洛替尼布 (每天8-12毫克,2周内/1周休息) 作为单疗法或组合疗法.
- 主要终点:无进展生存 (PFS);次要终点:整体生存 (OS),客观反应率 (ORR),疾病控制率 (DCR) 和不良事件 (AE) 通过CTCAE v5.0.0.
主要成果:
- 中位数PFS为9.4个月;6个月PFS率为62.1%.
- 平均生存期为12.7个月;12个月生存率为48.3%.
- ORR为72.4%,DCR为93.1%,III级AE的发病率很低 (3.4%),主要是血小板缺血.
结论:
- 安洛丁尼布在复发性高度质瘤中表现出有利的安全性,并具有可管理的不良事件.
- 该药物表现出显著的短期疗效,特别是延长PFS.
- 安洛丁尼布是复发性高度质瘤的一种有前途的治疗选择,需要进一步的临床研究.
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K